The notices it replaced
- Reissues: PAR-16-419 Exploratory Clinical Trials and Studies of Natural Products in NCCIH High Priority Research Topics (R33)
- 2 steps back: RFA-AT-16-002 Exploratory Clinical Trials of Natural Products in NCCIH High Priority Research Topics (R33)
Replaced by PAR-18-828.
Who won it before
1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $592,996 in first-year total cost, median $592,996.
Most frequent study sections
- Special Emphasis Panel[ZAT1 YW (01)]1
Most frequent institutions
- IMMUNOGENICS, LLC1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2017 | Latiglutenase as a Treatment for Celiac Disease1R33AT009637-01 · under PAR-16-419 | MURRAY, JOSEPH ASYAGE, JACK A. | IMMUNOGENICS, LLC, CA | $592,996 | ZAT1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.